Mizuho Securities Sticks to Their Buy Rating for Assembly Biosciences (ASMB)

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Assembly Biosciences (ASMBResearch Report), with a price target of $14.00. The company’s shares closed yesterday at $1.87.

Syed covers the Healthcare sector, focusing on stocks such as Cytokinetics, Atara Biotherapeutics, and Coherus Biosciences. According to TipRanks, Syed has an average return of -14.7% and a 36.67% success rate on recommended stocks.

Currently, the analyst consensus on Assembly Biosciences is a Moderate Buy with an average price target of $9.17.

See Insiders’ Hot Stocks on TipRanks >>

ASMB market cap is currently $90.58M and has a P/E ratio of -0.71.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.

Read More on ASMB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More